



Applicants Serial No.

: Simons et al.

Filed

: 09/145,916 : September 2, 1998

For

: "STIMULATION OF ANGIOGENESIS VIA ENHANCED

ENDOTHELIAL EXPRESSION OF SYNDECAN-4

CORE PROTEINS"

Examiner

: David Guzo

Group Art Unit

: 1636

Attorney's Docket No. : BIS-039

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on: <u>Jul4</u>

Attorney for applicants:_

Signature:

THIRD STATEMENT AND VERIFICATION OF SUBSTANTIVE IDENTITY BETWEEN THE THIRD COMPUTER READABLE FORM (CRF) COPY AND THE THIRD PAPER FORM COPY OF THE "SEQUENCE LISTING"

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

In substantive response to the Notice To Comply With Requirements

For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid

Sequence Disclosures mailed April 20, 2004 and extended through July 20, 2004, applicants' undersigned attorney states and verifies the following:

The content of the third paper form copy and the third computer readable form (CRF) copy of the "Sequence Listing" enclosed herewith are the same; the content of the third paper form copy and the third computer readable form (CRF) copy of the "Sequence Listings" enclosed herewith do not contain any New Matter; and the content of the third paper form copy and the third computer readable form (CRF) copy of the "Sequence Listing" enclosed herewith is fully supported by the descriptive and enabled disclosure of the Specification text originally filed September 2, 1998 as USSN 09/145,916.

This third statement and verification of the contents and sameness of the "Sequence Listing" in third paper form copy and third computer readable form (CRF) copy is made pursuant to and in compliance with the requirements as set forth in 37 C.F.R. 1.821-1.825 respectively. Applicants' undersigned attorney respectfully submits that this third statement and verification is also a legally complete and sufficient Response to the instant Notice to comply with requirements for sequence disclosures as such.

Respectfully submitted,

MICHAEL SIMONS **RUDIGER VOLK** ARIE HOROWITZ

Date: July 19, 2004
P.O. Box 5387
Magnolia, Massachusetts 01930
Tel.: (978) 525-3794

David Prashker Reg. No. 29,693 Attorney for applicants

JUL 2 1 2004

BEST AVAILABLE COPY

Application No.

09/145916

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING MUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the r	equirements of 37 CFR 1.821
- 1.825. Applicant's attention is directed to these regulation and 15, 1990 and at 55 FR 18230, May 1, 1990.	ons, published at 1114 OG 29
2. This application does not contain, as a separate paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c	
3. A copy of the "Sequence Listing" in computer readab submitted as required by 37 CFR 1.821(e).	le form has not been
4. A copy of the "Sequence Listing" in computer readable flowever, the content of the computer readable form does not constant of the computer readable form does not constant of 37 CFR 1.822 and/or 1.823, as indicated on the attached consequence Listing."	omply with the requirements
5. The computer readable form that has been filed with found to be damaged and/or unreadable as indicated on the attakeport. A substitute computer readable form must be submitted 1.825(d).	ched CRF Diskette Problem
6. The paper copy of the "Sequence Listing" is not the readable form of the "Sequence Listing" as required by 37 CFR	
7. Other:	
Applicant must provide:	•
An initial or substitute computer readable form (CRF) c Listing" An initial or substitute paper copy of the "Sequence Li	
An initial or substitute paper copy of the "Sequence Li amendment directing its entry into the specification	sting , as well as an
A statement that the content of the paper and computer and, where applicable, include no new matter, as required 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)	
For questions regarding compliance with these requi	rements, please contact

For Rules Interpretation, call (703) 308-1123 For CRF submission help, call (703) 308-4212 For PatentIn software help, call (703) 557-0400